About
LicensingInsightsBioLink WeeklyJob BoardNews中文Contact Us
Princeton, NJ — US-China Biopharma

Catalyzing US‑China
Biotech & Pharma Partnerships

BioRich International connects leading pharmaceutical companies and biotech innovators across the US-China corridor — facilitating licensing deals, capital connections, and R&D collaboration.

Explore Our ServicesRead BioLink Weekly
0+
Chinese Clients
0+
Projects
0+
MNC Connections
0+
Years of Experience
Our Services

Comprehensive Support Across the Deal Lifecycle

Licensing Deals

Out-licensing & in-licensing facilitation between Chinese biotechs and global pharma. 250+ clients, 400+ projects.

Learn more

Capital & Talent

We connect biopharma companies with pre-screened US venture capital and provide executive and scientific recruitment support — drawing on one of the most extensive personal networks in US-China biopharma to place the right people at the right time.

Learn more

CRO/CDMO Matching

Selecting the right contract research or manufacturing partner is one of the highest-stakes decisions in drug development. We leverage deep relationships across the China CRO/CDMO landscape — and beyond — to match clients with partners whose capabilities align with their program requirements.

Learn more

Market Research

Understanding the China biopharma market requires specialized knowledge that is difficult to source externally. Our proprietary market reports, combined with BioLink Weekly, provide the depth and currency needed to make confident strategic decisions.

Learn more
About BioRich

A Trusted Partner at the
Intersection of East and West

Founded by John Xu, MD, MBA, MS — with over 30 years of experience at Bristol Myers Squibb, Wyeth, WuXi AppTec, and CrownBio — BioRich International operates at the nexus of US and Chinese biopharma. We bridge the information, relationship, and cultural gaps that prevent high-potential deals from closing.

Our network encompasses 250+ Chinese biotech clients, direct relationships with BD&L leadership at 25+ multinational corporations, and active engagement with more than 10 US venture capital firms.

Meet our leadership
"

The biggest obstacle to deal-making is not interest or capital — it is information asymmetry. BioLink Weekly exists to close that gap.

John Xu, MD, MBA, MS

Founder & President, BioRich International

BioLink Weekly

Intelligence for US-China Biopharma Dealmakers

View all issues →
Issue 20August 25, 2026

US Dealmaking Stays Hot into Late August: BioMarin Buys Alesta for up to $490M, Sandoz Expands Its Shanghai Henlius Pact to up to 10 Biosimilars ($322M China-Out), and Merck-Moderna's mRNA Cancer Vaccine Clears Phase 3

US dealmaking stayed hot in the third week of August: BioMarin agreed to buy Alesta for up to $490M for an oral hypophosphatasia drug, while Sandoz widened its Shanghai Henlius biosimilar collaboration to as many as 10 products (up to $322M) - the week's clearest China-out signing. On the science side, Merck and Moderna's personalized mRNA cancer vaccine intismeran autogene became the first to clear a Phase 3 (in resected melanoma), Amylyx's avexitide hit in post-bariatric hypoglycemia, and AstraZeneca halted a volrustomig first-line lung-cancer Phase 3.

Read issue
Issue 19August 18, 2026

China-Out Licensing Reawakens as Almirall Taps Shenzhen's CrystalO for Dermatology, US Reverse-Mergers Return, and Ivonescimab Lands a Landmark China Approval

China-out partnering stirred again as Almirall licensed ex-China rights to Shenzhen-based CrystalO's ion-channel dermatology programs (announced Aug 10), while US dealmaking leaned on structure - Fulcrum and Slate agreed an all-stock reverse merger with a concurrent $245M financing, and PTC bought Sangamo's BLA-stage Fabry gene therapy ST-920 out of bankruptcy for $111M upfront. On the science side, China's NMPA approved Akeso's PD-1/VEGF bispecific ivonescimab in first-line squamous NSCLC, argenx's efgartigimod cleared Phase 3 ALKIVIA in autoimmune myositis, and Cullinan's zipalertinib hit its Phase 3 PFS endpoint in EGFR exon 20 NSCLC.

Read issue
Issue 18August 11, 2026

US Dealmaking Runs Hot as China-Out Licensing Pauses: Jazz Buys Actio for up to $1.3B, Biogen Closes an up-to-$1B RayThera Immunology Deal, and the AstraZeneca-BMS Mega-Merger Is Denied

US M&A carried the week - Jazz agreed to buy epilepsy biotech Actio Biosciences for up to $1.3B, Biogen closed its up-to-$1B RayThera immunology acquisition, and argenx opened its tender offer for vitiligo player Forte - while verified China-out licensing paused for a second week and Reuters reported there is no AstraZeneca-Bristol Myers merger after all. On the science side, MoonLake's IL-17 Nanobody sonelokimab cleared Phase 3 in psoriatic arthritis and Rhythm's MC4R agonist RM-718 posted an early obesity signal, while Tenax's oral levosimendan missed in PH-HFpEF.

Read issue

Ready to Explore a Partnership?

Whether you are seeking a licensing partner, an R&D collaborator, or strategic intelligence on the China market, we are ready to help.

Get in Touch